Arrowhead Pharmaceuticals Overview
- Year Founded
-
1989
- Status
-
Public
- Employees
-
609
- Stock Symbol
-
ARWR
- Investments
-
11
- Share Price
-
$13.80
- (As of Thursday Closing)
Arrowhead Pharmaceuticals General Information
Description
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting cardiovascular, Cardiometabolic, Central Nervous System, Pulmonary, Liver, Muscular, and Complement Mediated Disease. It majority products are liver disease curable.
Contact Information
Website
www.arrowheadpharma.comCorporate Office
- 177 East Colorado Boulevard
- Suite 700
- Pasadena, CA 91105
- United States
Corporate Office
- 177 East Colorado Boulevard
- Suite 700
- Pasadena, CA 91105
- United States
Arrowhead Pharmaceuticals Stock Performance
As of 27-Mar-2025, Arrowhead Pharmaceuticals’s stock price is $13.80. Its current market cap is $1.89B with 137M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $13.80 | $13.93 | $13.68 - $30.41 | $1.89B | 137M | 1.88M | -$5.16 |
Arrowhead Pharmaceuticals Financials Summary
As of 31-Dec-2024, Arrowhead Pharmaceuticals has a trailing 12-month revenue of $2.5M.
|
In Thousands, USD |
TTM 31-Dec-2024 | FY 2024 30-Sep-2024 | FY 2023 30-Sep-2023 | FY 2022 30-Sep-2022 |
|---|---|---|---|---|
| EV | 2,174,578 | 2,100,036 | 2,528,459 | 3,183,176 |
| Revenue | 2,500 | 3,551 | 240,735 | 243,231 |
| EBITDA | (608,208) | (584,228) | (190,971) | (167,321) |
| Net Income | (639,714) | (599,493) | (205,275) | (176,063) |
| Total Assets | 1,013,694 | 1,139,802 | 765,552 | 691,939 |
| Total Debt | 525,270 | 510,552 | 115,171 | 81,576 |
Arrowhead Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Arrowhead Pharmaceuticals Comparisons
Industry
Financing
Details
Arrowhead Pharmaceuticals Competitors (92)
One of Arrowhead Pharmaceuticals’s 92 competitors is Alnylam Pharmaceuticals, a Formerly VC-backed company based in Cambridge, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Alnylam Pharmaceuticals | Formerly VC-backed | Cambridge, MA | ||||
| Idorsia Pharmaceuticals | Corporate Backed or Acquired | Allschwil, Switzerland | ||||
| Alpine Immune Sciences | Pending Transaction (M&A) | Seattle, WA | ||||
| Dicerna Pharmaceuticals | Formerly VC-backed | Lexington, MA | ||||
| Regulus Therapeutics | Formerly VC-backed | San Diego, CA |
Arrowhead Pharmaceuticals Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Arrowhead Pharmaceuticals Patents
Arrowhead Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20250075214-A1 | Rnai agents for inhibiting expression of inhibin subunit beta e (inhbe), pharmaceutical compositions thereof, and methods of use | Pending | 30-Aug-2023 | ||
| US-20240167035-A1 | Rnai agents for inhibiting expression of complement component c3 (c3), pharmaceutical compositions thereof, and methods of use | Active | 27-Oct-2022 | ||
| US-12110492-B2 | Rnai agents for inhibiting expression of complement component c3 (c3), pharmaceutical compositions thereof, and methods of use | Active | 27-Oct-2022 | ||
| AU-2023330102-A1 | Methods for the treatment of angptl3-related diseases and disorders | Pending | 22-Aug-2022 | ||
| US-20240026363-A1 | Rnai agents for inhibiting expression of superoxide dismutase 1 (sod1), compositions thereof, and methods of use | Active | 15-Jun-2022 | C12N15/1137 |
Arrowhead Pharmaceuticals Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Arrowhead Pharmaceuticals Investments & Acquisitions (11)
Arrowhead Pharmaceuticals’s most recent deal was a Joint Venture with Visirna Therapeutics for . The deal was made on 29-Apr-2022.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Visirna Therapeutics | 29-Apr-2022 | Joint Venture | Drug Discovery | ||
| Visirna(Arrowhead/Vivo) | 25-Apr-2022 | Early Stage VC | Drug Discovery | ||
| Novartis (RNAI Research and Development Portfolio) | 05-Mar-2015 | Merger/Acquisition | Biotechnology | ||
| Alvos Therapeutics | 11-Apr-2012 | Merger/Acquisition | Drug Discovery | ||
| Roche Holding (RNA Therapeutics Business) | 24-Oct-2011 | Merger/Acquisition | Drug Delivery |
Arrowhead Pharmaceuticals ESG
Risk Overview
Risk Rating
Updated March, 01, 2024
25.8 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,946
Rank
Percentile
Pharmaceuticals
Industry
of 847
Rank
Percentile
Biotechnology
Subindustry
of 366
Rank
Percentile
Arrowhead Pharmaceuticals Exits (5)
Arrowhead Pharmaceuticals’s most recent exit was on 01-Aug-2008 from Unidym. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Unidym | 01-Aug-2008 | Completed |
|
||
| Unidym | 17-Jun-2008 | Completed |
|
||
| Calando Pharmaceuticals | 16-Oct-2006 | Completed |
|
||
| Calando Pharmaceuticals | 04-Jun-2004 | Completed |
|
||
| Unidym | Later Stage VC | Completed |
Arrowhead Pharmaceuticals FAQs
-
When was Arrowhead Pharmaceuticals founded?
Arrowhead Pharmaceuticals was founded in 1989.
-
Where is Arrowhead Pharmaceuticals headquartered?
Arrowhead Pharmaceuticals is headquartered in Pasadena, CA.
-
What is the size of Arrowhead Pharmaceuticals?
Arrowhead Pharmaceuticals has 609 total employees.
-
What industry is Arrowhead Pharmaceuticals in?
Arrowhead Pharmaceuticals’s primary industry is Biotechnology.
-
Is Arrowhead Pharmaceuticals a private or public company?
Arrowhead Pharmaceuticals is a Public company.
-
What is Arrowhead Pharmaceuticals’s stock symbol?
The ticker symbol for Arrowhead Pharmaceuticals is ARWR.
-
What is the current stock price of Arrowhead Pharmaceuticals?
As of 27-Mar-2025 the stock price of Arrowhead Pharmaceuticals is $13.80.
-
What is the current market cap of Arrowhead Pharmaceuticals?
The current market capitalization of Arrowhead Pharmaceuticals is $1.89B.
-
What is Arrowhead Pharmaceuticals’s current revenue?
The trailing twelve month revenue for Arrowhead Pharmaceuticals is $2.5M.
-
Who are Arrowhead Pharmaceuticals’s competitors?
Alnylam Pharmaceuticals, Idorsia Pharmaceuticals, Alpine Immune Sciences, Dicerna Pharmaceuticals, and Regulus Therapeutics are some of the 92 competitors of Arrowhead Pharmaceuticals.
-
What is Arrowhead Pharmaceuticals’s annual earnings per share (EPS)?
Arrowhead Pharmaceuticals’s EPS for 12 months was -$5.16.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
